BACKGROUND: The diagnosis of inflammatory bowel disease is often delayed because of the lack of an ability to recognize its major clinical manifestations. OBJECTIVE: Our study aimed to describe the onset of clinical manifestations in inflammatory bowel disease patients. METHODS: A cross-sectional study. Investigators obtained data from interviews and the medical records of inflammatory bowel disease patients from a reference centre located in Brazil. RESULTS: A total of 306 patients were included. The mean time between onset of symptoms and diagnosis was 28 months for Crohn’s disease and 19 months for ulcerative colitis. The main clinical manifestations in Crohn’s disease patients were weight loss, abdominal pain, diarrhoea and asthenia. The most relevant symptoms in ulcerative colitis patients were blood in the stool, faecal urgency, diarrhoea, mucus in the stool, weight loss, abdominal pain and asthenia. It was observed that weight loss, abdominal pain and distension, asthenia, appetite loss, anaemia, insomnia, fever, nausea, perianal disease, extraintestinal manifestation, oral thrush, vomiting and abdominal mass were more frequent in Crohn’s patients than in ulcerative colitis patients. The frequencies of urgency, faecal incontinence, faeces with mucus and blood, tenesmus and constipation were higher in ulcerative colitis patients than in Crohn’s disease patients. The mean time from the onset of clinical symptoms to the diagnosis of Crohn’s disease was 37 months for patients with ileocolonic location, 26 months for patients with ileum location and 18 months for patients with colon location. In ulcerative colitis patients, the mean time from the onset of symptoms to diagnosis was 52 months for proctitis, 12 months for left-sided colitis and 12 months for extensive colitis. CONCLUSION: Ulcerative colitis presented a high frequency of intestinal symptoms, and Crohn’s disease showed a high frequency of systemic manifestations at the onset of manifestation. There was a long delay in diagnosis, but individuals with more extensive disease and more obvious symptoms showed a shorter delay.

Background. In inflammatory bowel disease (IBD) patients there are reports of the occurrence of hepatobiliary manifestations, so the aim of this study was to evaluate the hepatobiliary manifestations in patients with Crohn’s disease (CD) and ulcerative colitis (UC) from an IBD reference center. Methods. Cross-sectional study in an IBD reference center, with interviews and review of medical charts, between July 2015 and August 2016. A questionnaire addressing epidemiological and clinical characteristics was used. Results. We interviewed 306 patients, and the majority had UC (53.9%) and were female (61.8%). Hepatobiliary manifestations were observed in 60 (19.6%) patients with IBD. In the greater part of the patients (56.7%) hepatobiliary disorders were detected after the diagnosis of IBD. In UC (18.2%) patients, the hepatobiliary disorders identified were 11 (6.7%) non-alcoholic fatty liver disease, 9 (5.5%) cholelithiasis, 6 (3.6%) primary sclerosing cholangitis (PSC), 3 (1.8%) hepatotoxicity associated with azathioprine, 1 (0.6%) hepatitis B, and 1 (0.6%) hepatic fibrosis. In CD (21.3%) patients, 11 (7.8%) had cholelithiasis, 11 (7.8%) non-alcoholic fatty liver disease, 4 (2.8%) PSC, 3 (2.1%) hepatotoxicity, 1 (0.7%) hepatitis B, (0.7%) hepatitis C, 1 (0.7%) alcoholic liver disease, and 1 (0.7%) autoimmune hepatitis (AIH). There was one case of PSC/AIH overlap syndrome. Conclusion. The frequency of hepatobiliary disorders was similar in both forms of IBD in patients evaluated. The most common nonspecific hepatobiliary manifestations in IBD patients were non-alcoholic liver disease and cholelithiasis. The most common specific hepatobiliary disorder was PSC in patients with extensive UC or ileocolonic CD involvement; this was seen more frequently in male patients.

No abstract

No abstract

Instituição: SSP INTRODUÇÃO: Dentre o arsenal terapêutico das doenças inflamatórias intestinais(DII), temos a terapia biológica e, dentre, estes, os anti-TNF, como infliximabe (IFX) e adalimumabe (ADA). OBJETIVO: Descrever o perfil dos pacientes com doença inflamatória intestinal em uso de terapia biológica em uma unidade hospitalar pública. MÉTODO: Estudo transversal de julho/2015 a agosto/2016, com entrevista de pacientes e revisão de prontuários, em centro de referência de DII em Salvador, Bahia, com análise dos dados com uso do programa SPSS, versão 21.0 RESULTADOS: 306 pacientes com DII -11,4% (35) em uso de biológicos. Destes, 54,3% (19) usavam IFX e 45,7% (16) ADA. Dos 19 pacientes em uso de IFX, 57,9% (11) eram do sexo feminino e 42,1% (8) do sexo masculino; 94,7% (18) com Doença de Crohn (DC) e 5,3% (1) Retocolite Ulcerativa (RCU). Segundo o Índice Harvey-Bradshow, 72,2% (13) dos portadores de DC estavam com doença em remissão, 22,2% (4) leve-moderada, 5,5% (1) moderada-grave; a 5,5% (1) foi diagnosticado com menos de 16 anos, 72,2% (13) entre 17 e 40 anos e 22,2% (4) com mais de 40 anos; 11,1% (2) com acometimento ileal, 38,9% (7) colônica e 44,4% (8) ileocolônica; 27,8% (5) com forma inflamatória, 11,1% (2) estenosante e 61,1% (11) penetrante; apenas 5,5% (N=1) apresentou acometimento do TGI superior e 61,1% (11) com doença perianal associada; O único paciente com RCU, segundo o Índice Lichtiger, estava em remissão e apresentava colite extensa. Dentre os 16 pacientes em uso de ADA, 56,2% (9) do sexo feminino e 43,8% (7) do sexo masculino; 100% (16) com DC. Segundo o Índice Harvey-Bradshow, 62,5% (10) encontravamse em remissão, 18,75% (3) e leve a moderada, 12,5% (2) em moderada a grave; 25% (4) diagnosticados até os 16 anos, 62,5% (N=10) entre 17-40 e 12,5% (2) com mais de 40 anos; de acordo com a localização, 31,25% (5) tiveram localização ileal, 25% (4) colônica e 37,5% (6) ileocolônica; em relação ao comportamento, 43,7% (7) apresentaram a forma inflamatória, 43,7% (7) estenosante e 12,5% (2) penetrante; nenhum paciente apresentou acometimento do TGI superior; 43,7% (7) apresentaram doença perianal. CONCLUSÃO: O uso de IFX e ADA foi predominante em pacientes do sexo feminino, com DC ileocolônica em remissão, sendo a maioria diagnosticada entre 17 e 40 anos. A forma penetrante da doença é a mais predominante naqueles em uso de IFX e a que menos ocorreu naqueles em uso de ADA. ABCDExpress 2017;1(2):1088Codigo: 64244 Acesso está disponível em www.revistaabcd.com.br e www.sbad2017.com.br Acesso pelo